Clinical Trial Update: Canakinumab for Pyoderma Gangrenosum [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating canakinumab for Pyoderma Gangrenosum has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pyoderma Gangrenosum

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: University of Zurich | Conditions: Pyoderma Gangrenosum | Phase 2 | Status: COMPLETED